Introduction
============

Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cell carcinoma (RCC), accounting for most of RCC-related deaths [@B1]. Although surgery can be curative at the early-stage, deaths due to kidney cancer have not declined primarily because of recurrence and metastasis [@B2]. Traditional treatment modalities, such as chemotherapy and radiotherapy, do not significantly improve the response rates or survival in metastatic disease [@B3]. For metastatic cases, cytoreductive nephrectomy with immunotherapy has shown significant increase in long-term survival [@B4]. In the 20th century, Fyfe *et al.* demonstrated a 15% objective response rate in RCC patients who treated with high-dose IL-2, this lead the US Food and Drug Administration (FDA) to approve the use of IL-2[@B5]. However, the treatment-related mortality rate of up to 4% [@B5] ratifies the urge for newer, novel and improved therapeutics for ccRCC patients.

Presently, immune evasion was added to the list of hallmarks required for tumour formation and metastasis [@B6]. Several specific immune features in the microenvironment suggest that an ongoing tumour-directed immune response is limited by the interaction between PD-1 and PD-L1 [@B7]. Currently, several unique clinical trials have shown that the responses to PD-1/PD-L1 checkpoint inhibitions are more frequently observed among ccRCC patients with positively expressed tumour cell PD-L1 (TC-PD-L1) [@B8]-[@B12]. However, these trails had varying percentage of positivity, ranging from 15% to 66%. In addition, Callea M*et al.* detected the heterogeneity of TC-PD-L1 expression between primary and metastatic sites [@B11]. However, ccRCC is characterized by intratumoural heterogeneity [@B13]. Therefore, the expression patterns of TC-PD-L1 in the local microenvironment of ccRCC cannot be ignored.

As such, in this study we systematically estimated the expression patterns of TC-PD-L1 in the local tumour microenvironment of ccRCC and observed a positive association between TC-PD-L1 and CD8^+^ TILs. The intrinsic and extrinsic expression patterns are both detected in ccRCC. Moreover, CD8^+^ TILs were associated with significantly poor survival in TC-PD-L1-positive ccRCC patients, which thereby underscore an urge for improved treatment options in these patients.

Materials and Methods
=====================

Cell lines
----------

We obtained five cell lines (ACHN, Caki-1, A498, 769-P, and 786-O) and immortalized proximal tubular cell line HK2 from the American Type Culture Collection. The cells were cultured in the RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Life Technologies) and 1% penicillin-streptomycin at 37°C in a humidified atmosphere containing 5% CO~2~. For the IFNγ stimulation experiments, cells were seeded at 100,000 cells/well in six-well plates then incubated in the presence (20 or 40 ng/ml) or in the absence of IFNγ (Proteintech).

Tissue specimens and patient information
----------------------------------------

Retrospective assessment of a cohort of 135 primary ccRCC patients treated with radical or conservative surgery with or without a tyrosine kinase inhibitor (TKI)-based targeted therapy (sunitinib/sorafenib), between January 2009 and August 2013 at the Urology Department at Sun Yat-sen University Cancer Center (Guangzhou, China) was performed. Tumour grading and staging were classified according to the 7^th^ AJCC Staging System edition. Fresh primary tissue samples were retrieved from the Pathology Department at the Medical College in Nanchang University (Nanchang, China). Overall survival (OS) was calculated from the date of diagnosis to the date of death. Disease-free survival (DFS) was calculated from the date of diagnosis to the date of first recurrence or distant metastasis (irrespective of the site) till the date of death (irrespective of the cause) or last follow-up visit.

Immunohistochemistry and evaluation
-----------------------------------

Briefly, 5-μm-thick paraffin sections were deparaffinized with xylene and rehydrated in the water. The sections were submerged into EDTA (1 mmol/L, pH = 9.0) and microwaved for antigenic retrieval. 3% hydrogen peroxide was used to quench endogenous peroxidase activity. The addition of goat serum was used to block nonspecific binding. The slides were selectively incubated with either a rabbit anti-human PD-L1 monoclonal antibody (mAb) (1:100; \#13684, Cell Signaling Technology) or a rabbit anti-CD8 polyclonal antibody (1:100; Golden Bridge Biotech, Beijing, China) overnight at 4°C, washed 5 times with PBS and incubated with HRP-conjugated secondary antibodies (Envision^TM^ Detection Kit, GK500705, Gene Tech) for 30 min. 3,3\'-Diaminobenzidine (DAB) was used to develop positive identification signals, after which they were counterstained with hematoxylin. Lastly, the sections were dehydrated and evaluated.

Scoring evaluations were performed by two expert pathologists (Min Li and Mu-Yan Cai) blinded from the patients\' outcomes. The percentage of PD-L1-positive cells occupying the tumour was scored as follows: 0, \< 5% of the area; or 1, ≥ 5% of cells of the area. Cases demonstrating ≥ 5% tumour cell expression were considered positive to maintain consistency with previous literatures [@B14]-[@B16]. Meanwhile, we counted the number of CD8^+^ TILs in five random fields at 200× magnification and for which the average value was obtained [@B17]. The median of CD8^+^ TILs counts was identified as the optimal cut-off value.

Reverse transcription-polymerase chain reaction
-----------------------------------------------

Total RNA was extracted from tumour samples using the TRIzol reagent (Sigma-Aldrich). Complementary DNA (cDNA) was synthesized using a GoScript^TM^ Reverse Transcription System (Promega), and qPCR was conducted using GoScript qPCR Master Mix (Promega). The forward and reverse primer sequences for PD-L1 were 5\'-CCTACTGGCATTTGCTGAACGCAT-3\' and 5\'-ACCATAGCTGATCATGCAGCGGTA-3\', respectively; for CD8^+^ were 5\'-ATGGCCTTACCAGTGACCG-3\' and 5\'-AGGTTCCAGGTCCGATCCAG-3\', respectively; for IFNγ were 5\'-TCGGTAACTGACTTGAATGTCCA-3\' and 5\'-TCGCTTCCCTGTTTTAGCTGC-3\', respectively; and for GAPDH were 5\'-TTCTTTTGCGTCGCCAGCCGA-3\' and 5\'-GTGACCAGGCGCCCAATACGA-3\', respectively. The relative expression was calculated as follows: 2^-ΔCt^, where ΔCt is Ct(gene) - Ct(GAPDH).

Western blot analysis
---------------------

30 μg of proteins underwent electrophoresis in 10% SDS-PAGE, and then transferred on the polyvinylidene fluoride membranes (Immobilon P; Millipore, Bedford, MA, USA). The membranes were blocked with 5% nonfat milk for 60 min and incubated with rabbit anti-PD-L1 (1:1,000, Cell Signaling Technology) or rabbit monoclonal anti-GAPDH (1:5000, Cell Signaling Technology) overnight at 4°C. Afterwards, HRP-conjugated secondary antibody (1:10000, sc-2004, Santa Cruz Biotechnology) was incubated with membranes, and the bands were visualized using a ChemiDoc Touch (Bio-Rad). The intensity of the bands was measured and normalized to GAPDH by using ImageJ software (NIH, Bethesda, MD, USA).

Statistical analysis
--------------------

All statistical computations were performed using SPSS 19.0. Spearman\'s rank correlation was used to analyse the CD8^+^ TILs and TC-PD-L1 expression levels as continuous variables. The chi-squared test was used to determine the association between either TC-PD-L1 expression or the CD8^+^ TIL count with the patients\' clinicopathological features. The correlations among the mRNA expression levels of PD-L1, CD8^+^ and IFNγ were analysed using Spearman\'s rank correlation. Kaplan-Meier method was used to depict the survival curves. The log-rank test was conducted to compare the difference. Cox proportional hazards model was performed for univariate analyses and multivariate analysis. A *P* value less than 0.05 (two-sided) were used to denote statistically significant.

Results
=======

Clinicopathological features of the patients
--------------------------------------------

The average age was 52 years (range 14-78 years), and there were twice as many male patients (n = 91) than female patients (n = 44) in the cohort. Among these patients, 83 (61.5%) patients were diagnosed with clinical stage I, 24 (17.8%) with stage II, 12 (8.9%) with stage III, and 16 (11.8%) with stage IV disease. Over a median follow-up time of 60 months, 27 (20.0%) patients relapsed, and 23 (17.0%) died. The clinicopathological characteristics of the 135 included ccRCC patients are presented in Table [1](#T1){ref-type="table"}.

Elevated TC-PD-L1 expression associates with higher CD8^+^ TILs infiltration and advanced clinicopathological features in ccRCC
-------------------------------------------------------------------------------------------------------------------------------

Representative images of TC-PD-L1 expression and CD8^+^ T lymphocytes from each classification are depicted in Figure [1](#F1){ref-type="fig"}a. PD-L1 expression was predominantly localized to the cell membrane, and 51 (37.8%) ccRCC patients in our cohort demonstrated positive PD-L1 staining. We further evaluated the association of PD-L1 expression and the presence of CD8^+^ TILs and observed that PD-L1 expression in tumour cells was significantly correlated with CD8^+^ T lymphocyte infiltration (r = 0.505, *P* \< 0.001, Figure [1](#F1){ref-type="fig"}b). Similar results were obtained when TC-PD-L1 expression and CD8^+^ TILs were analysed as categorical variables (*P* \< 0.001, Table [1](#T1){ref-type="table"}). Meanwhile, TC-PD-L1 expression was shown to be associated with clinical stage (*P* = 0.027) and tumour size (*P* = 0.004); however, no significant association was observed between TC-PD-L1 expression and the patients\' gender, age, tumour location, Fuhrman classification, smoking history, blood creatinine (Cr) or blood urea nitrogen (BUN) (Table [1](#T1){ref-type="table"}).

Intrinsic and extrinsic PD-L1 expression patterns in ccRCC
----------------------------------------------------------

PD-L1 protein and mRNA expression were detected in ccRCC cell lines (ACHN, Caki-1, A498, 769-P, and 786-O) using western blotting and RT-PCR. As illustrated in Figure [2](#F2){ref-type="fig"}a and [2](#F2){ref-type="fig"}b, TC-PD-L1 expression was relatively higher in cell line ACHN, 769-P and 786-O compared with Caki-1 and A498. The expression of TC-PD-L1 in ccRCC cell line was further confirmed at the mRNA level. To investigate whether PD-L1 expression in ccRCC cancer cells could be stimulated by IFNγ, ccRCC cell lines were incubated with several concentrations of IFNγ (0, 20 and 40 ng/mL). After 48 hours of IFNγ administration, PD-L1 expression was significantly elevated (Figure [2](#F2){ref-type="fig"}c and d). To further elucidate the underlying mechanisms responsible for the association between elevated TC-PD-L1 and CD8^+^ TIL infiltration at mRNA level, a cohort of 30 primary clear cell renal carcinoma specimens was used. Similar results demonstrating significant positive correlation between PD-L1 to either IFNγ or CD8 was observed (r = 0.624, *P* \< 0.001 and r = 0.545, *P* = 0.002; Figure [2](#F2){ref-type="fig"}e and [2](#F2){ref-type="fig"}f, respectively).

Association of PD-L1 expression and CD8^+^ infiltration levels with prognosis
-----------------------------------------------------------------------------

The Kaplan-Meier curves showed that patients with positively expressed TC-PD-L1 had worse OS and DFS (*P* = 0.006 and 0.017, Figure [3](#F3){ref-type="fig"}a and [3](#F3){ref-type="fig"}b, respectively). Moreover, our results demonstrated patients with abundant CD8^+^ TILs infiltration experienced poorer OS and DFS (both *P* \< 0.001, Figure [3](#F3){ref-type="fig"}c and [3](#F3){ref-type="fig"}d, respectively). Intriguingly, subgroup analysis detected more distinct differences in survival when TC-PD-L1-positive ccRCC patients were sub-classified as with or without CD8^+^ T cell infiltration (OS and DFS, *P* = 0.023 and *P* = 0.022, respectively, Figure [4](#F4){ref-type="fig"}). Univariate analysis revealed higher risks of death (HR, 2.519; *P* = 0.001) and disease relapse (HR, 2.285; *P* = 0.001) in patients with high levels of CD8^+^ TILs (Table [2](#T2){ref-type="table"}). Multivariate Cox regression analysis identified that CD8^+^ TILs and clinical stage as independent prognostic factors for a worse OS (*P* = 0.038 and *P* \< 0.001, respectively) and DFS (*P* = 0.011 and *P* \< 0.001, respectively; Table [2](#T2){ref-type="table"}), while TC-PD-L1 expression was not identified as an independent prognostic factor.

Discussion
==========

Numerous reports have detected PD-L1 expression in primary RCC, whereas highly variable percentages of the positive tumour area were reported ranging from 15% to 66% [@B8]-[@B10], [@B16], [@B18]-[@B20]. In ours, the detection rate was 37.8%, similar to previous reports with positivity rates of 32% [@B11] and 37.2% [@B12] in ccRCC, indicating the heterogeneity PD-L1 expression among the subtypes of RCC cannot be ignored. Meanwhile, our study observed that patients with higher TC-PD-L1 expression have increased CD8^+^ immune cell infiltration. The ccRCC cell line treated with increasing concentrations of recombinant IFNγ led to an increase in PD-L1 expression. These findings underscore the mechanism that CD8^+^ TILs recruited into the local environment release IFNγ thus driving PD-L1 expression and reflect the presence of an adaptive immune resistance in ccRCC patients. Further, the absence of the CD8^+^ TILs infiltration in high expressing TC-PD-L1 was identified as being 23% (12/51), which demonstrated the existence of intrinsic immune resistance in ccRCC patients. According to the previous criteria [@B21], [@B22], 23% PD-L1 positive expression ccRCC patients detected in present study may fail to respond to the treatments of PD-1/PD-L1 inhibitions for the lack of pre-existing T cell infiltrates, combination therapy designed to bring the T cells into tumours would be considered. Additionally, RCC patients with higher TC-PD-L1 have been demonstrated to be related to the increased tumour aggressiveness such as a higher TNM stage and larger tumour size [@B12], [@B23]-[@B25]. Our study also reported significantly difference of TC-PD-L1 expression in disease stage and tumour size at presentation indicating that checkpoint inhibitions may have activity in patients with late stage disease or a high tumour burden.

Immunohistochemical studies have concluded that CD8^+^ TILs exert antitumour activities, which indicates that CD8^+^ TILs must serve as a positive\\prognostic factor. In contrast, Osamu Nakano *et al.* found that patients with more abundant CD8^+^ TILs infiltration experienced poorer survival and suggested the immune cell reactions are more pronounced as the biological malignancy progresses for the increased antigenicity of tumour cell [@B26]. The present study detected similar negative association of high CD8^+^ T cell infiltration with survival. Further analysis revealed that TC-PD-L1-positive ccRCC patients with high concentration of CD8^+^ TILs infiltration were associated with a poor prognosis, underscoring a need for improved treatment options in these patients. This seemingly paradoxical observation supports the new idea that the adaptive resistance is active in the tumour microenvironment [@B14], [@B27], [@B28]. In that scenario, TC-PD-L1 can interact with its receptor thus inducing CD8^+^ TILs anergy or exhaustion[@B29] . Moreover, previous study observed the expression of genes that were associated with immunosuppression (PD-L1, IDO1, and Tregs) was associated with the presence of CD8^+^ TILs and INFγ [@B30]. Likely due to the highly suppressive process in the local microenvironment, the poor prognosis was detected in the subgroup analysis. However, for the limited number of patients, further prospective research is needed.

To the best of our knowledge, the present study is the first to comprehensively and specifically investigate the PD-L1 expression patterns in the primary microenvironment. However, inevitable selection bias may exist in this retrospective study.

Conclusion
==========

The CD8^+^ TILs were elucidated to influence the expression of TC-PD-L1 in ccRCC patients and associated with significant poor survival in TC-PD-L1-positive ccRCC patients.
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![**Evaluation of PD-L1 expression, CD8^+^ TILs and their associations in 135 ccRCC tissues. (a)** Representative images of TC-PD-L1 expression and CD8^+^ TILs, ×200 magnification. **(b)** The significantly positive correlation between the positive rate of TC-PD-L1 and the number of CD8^+^ TILs as continuous variables.](jcav10p1154g001){#F1}

![**Correlation between PD-L1 expression and IFN**γ **or CD8^+^ in ccRCC. (a)** PD-L1 protein in ccRCC cell lines was detected by western blotting. **(b)** PD-L1 mRNA in ccRCC cell lines. **(c)** PD-L1 protein was detected after incubated with several concentrations of IFNγ (0, 20 and 40 ng/mL) for 48 h. GAPDH was used as an internal loading control. **(d)**The target protein levels were normalized to the corresponding GAPDH protein levels. **(e)** The significant positive correlation between the mRNA of PD-L1 and IFNγ as well as **(f)** PD-L1 and CD8^+^ in 30 ccRCC tumour tissues.](jcav10p1154g002){#F2}

![**Comparison of survival according to PD-L1 expression in tumour cell and the number of CD8^+^ TILs. (a)** Overall survival and **(b)** disease-free survival were significantly enhanced in TC-PD-L1^neg^ patients compared with TC-PD-L1^pos^ patients. **(c)** Overall survival and **(d)** disease-free survival were significantly poor in patients with high CD8^+^ TILs infiltration compared with low CD8^+^ TILs infiltration. The small vertical tick marks of "Obs" represented the observed number of events patients. The "number of patients at risk" represented the number of patient possible happened events in the follow-up time.](jcav10p1154g003){#F3}

![**Subgroup survival analysis based on the CD8^+^ TILs in TC-PD-L1-positive ccRCC patients. (a)**Kaplan-Meier curves for overall survival and **(b)** disease-free survival in TC-PD-L1-positive patients with abundant or absence of CD8^+^ TILs infiltration. \"Obs\" means the observed number of events patients. The \"number of patients at risk\" represented the number of patient possible happened events in the follow-up time.](jcav10p1154g004){#F4}

###### 

Association between tumour cell PD-L1 expression and the clinicopathological features of clear cell renal cell carcinoma

  Feature                                   PD-L1 expression                             
  ---------------------------- ------------ ------------------ ----------- ------------- --
  **Gender**                                                                             
  Female                       44(32.6%)    22(50.0%)          22(50.0%)   0.058         
  Male                         91(67.4%)    62(68.1%)          29(31.9%)                 
  **Age (years)**                                                                        
  \< 50                        59(43.7%)    40(67.8%)          19(32.2%)   0.284         
  ≥50                          76(56.3%)    44(57.9%)          32(42.1%)                 
  **Tumour size**                                                                        
  \<5cm                        62(45.9%)    47(75.8%)          15(24.2%)   **0.004**     
  ≥5cm                         73(54.1%)    37(50.7%)          36(49.3%)                 
  **Tumour location**                                                                    
  Left                         81(60.0%)    51(63.0%)          30(37.0%)   0.858         
  Right                        54(40.0%)    33(61.1%)          21(38.9%)                 
  **Clinical Stage**                                                                     
  I-II                         107(79.3%)   72(67.3%)          35(32.7%)   **0.027**     
  III-IV                       28(20.7%)    12(42.9%)          16(57.1%)                 
  **Fuhrman classification**                                                             
  I-II                         110(81.5%)   71(64.5%)          39(35.5%)   0.261         
  III-IV                       25(18.5%)    13(52.0%)          12(48.0%)                 
  **Smoking history**                                                                    
  No                           87(64.4%)    51(58.6%)          36(41.4%)   0.271         
  Yes                          48(35.6%)    33(68.8%)          15(31.3%)                 
  **Cr**                                                                                 
  Normal                       116(85.9%)   69(59.5%)          47(40.5%)   0.130         
  High                         19(14.1%)    15(78.9%)          4(21.1%)                  
  **BUN**                                                                                
  Normal                       120(88.9%)   73(60.8%)          47(39.2%)   0.409         
  High                         15(11.1%)    11(73.3%)          4(26.7%)                  
  **Vital status**                                                                       
  Alive                        112(83.0%)   75(67.0%)          37(33.0%)   **0.018**     
  Dead                         23(17.0%)    9(39.1%)           14(60.9%)                 
  **CD8^+^TILs**                                                                         
  Low                          67(49.6%)    55(82.1%)          12(17.9%)   **\<0.001**   
  High                         68(50.4%)    29(42.6%)          39(57.4%)                 

Cr, creatinine; BUN, urea nitrogen.

###### 

Univariate and multivariate Cox regression analysis of the association of various clinicopathological features with overall survival and disease-free survival in patients with clear cell renal cell carcinoma

  Feature                                     Overall survival                      Disease-free survival                          
  ------------------------------------------- ----------------------- ------------- ----------------------- ---------------------- -------------
  I                                                                                                                                
  Gender (F *vs* M)                           -0.528(0.259-1.346)     0.210                                 -0.428(0.302-1.405)    0.275
  Age, years (\<50 *vs* ≥50)                  0.656(0.792-4.684)      0.148                                 0.723(0.902-4.708)     0.086
  Tumour size (\<5cm *vs* ≥5cm)               1.257(1.304-9.472)      **0.013**                             1.022(1.175-6.578)     **0.020**
  Tumour location (Left*vs* Right)            0.703(0.796-5.125)      0.139                                 0.745(0.890-4.981)     0.090
  Clinical Stage (I,II vs III,Iv)             3.808(13.210-153.575)   **\<0.001**                           3.222(9.927-63.303)    **\<0.001**
  Fuhrman classification (I,II *vs* III,Iv)   1.617(2.215-11.449)     **\<0.001**                           1.665(2.476-11.273)    **\<0.001**
  Smoking history (No *vs* Yes)               0.161(0.509-2.715)      0.706                                 0.054(0.483-2.305)     0.893
  Cr (Normal *vs* High)                       -1.363(0.035-1.899)     0.183                                 -0.755(0.111-1.984)    0.304
  BUN (Normal *vs* High)                      -1.053(0.047-2.588)     0.303                                 -0.432(0.154-2.741)    0.557
  TC-PD-L1 (Negative *vs* Positive)           1.103(1.304-6.970)      **0.010**                             0.893(1.142-5.222)     **0.021**
  CD8^+^ TILs (Low *vs* High)                 2.519(2.909-53.000)     **0.001**                             2.285(2.956-32.679)    **0.001**
  II                                                                                                                               
  Tumor size (\<5cm *vs* ≥5cm)                0.709(0.706-5.855)      0.189                                 0.266(0.469-3.626)     0.610
  Clinical Stage (I,II *vs* III,Iv)           3.282(7.504-94.491)     **\<0.001**                           2.774(5.996-42.825)    **\<0.001**
  Fuhrman classification (I,II vs III,Iv)     1.368(0.523-3.575)      0.523                                 0.539(0.669-4.393)     0.262
  TC-PD-L1 (Negative *vs* Positive)           0.303(0.517-3.542)      0.537                                 0.050(0.456-2.422)     0.907
  CD8^+^ TILs (Low*vs* High)                  1.693(1.099-26.897)     **0.038**                             1.719 (1.494-20.842)   **0.011**

Cr, creatinine; BUN, urea nitrogen.
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